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Role of polypeptide growth factors in normal and abnormal
growth
LEONARD M. PATT and JOHN C. HOUCK
Virginia Mason Research Center, Seattle, Washington
There are three general conditions in which cell growth
occurs in animals. The first is during embryonic growth and
subsequent development into an adult organism. Second, there
is the cellular proliferation in response to an injury such as
wound repair and, of special interest here, in compensatory
growth. Finally, there is the rapid growth associated with the
neoplastic transformation of cells and resulting tumor growth.
In this short review we will present several examples of the best
characterized factors which have been associated with one or
more of these situations. As with most biologically active
factors, it is impossible to make clear cut-cut dividing lines as to
function and several factors can be implicated several places.
For example, nerve growth factor may play a role both in
normal neuronal development and wound repair. Also, growth
factors active in neoplastic growth may be involved in embry-
onic development. Both these cases will be mentioned in detail
later.
Throughout this review, growth will be defined so as to
include both an increase in the number of cells, hyperplasia,
and the enlargement and extension of individual cells, hypertro-
phy. There are instances, however, where a distinction must be
made. There has been an explosive proliferation in research
findings concerning growth factors in the last 10 years, partially
made possible by the commercial availability of several of the
best characterized factors. Numerous literature makes it neces-
sary to omit certain details here and, thus, no attempt will be
made to detail the most recent theories on how growth factors
transmit the mitogenic message once they interact with the
target cells. For example, several recent reviews discussed in
detail how this may occur as well as structural similarities of
several factors [1—31.
In brief, we will summarize the current knowledge of growth
factors in relationship to the three common situations where
they are known to act; normal growth, response to injury, and
neoplastic growth. The participation of growth factors has been
well established in these situations, although there are other
factors involved such as the substratum supporting the cells [4,
5] and growth-inhibiting substances [6, 71, some of which will be
mentioned where necessary.
Normal development and functions
Epidermal growth factor. Epidermal growth factor (EGF) is
perhaps the best characterized and certainly the most studied of
all the growth factors. EGF was identified initially in extracts of
mouse submaxillary glands [8, 9]. The primary biological activi-
ty used to isolate EGF was premature eyelid opening in
neonatal mice. Control newborn mice open their eyes at 12 days
after birth while mice injected with 1 tgIg body weight of
purified EGF open them at 8 days and 0.25 rg/g at 10 days.
EGF isolated from mouse submaxillary glands is an acidic
polypeptide with an isoelectric point of 4.6 and molecular
weight of 6045 whose complete amino acid sequence is known
[10]. EGF is usually found associated in tissue with a high
molecular weight carrier protein which has been identified as an
arginine esterase which releases the terminal amino acids from
precursors of EGF [10]. A molecule with properties similar to
mouse EGF has been isolated from human urine [111. In
addition, it has been found that mouse EGF and human
urogastrone share a common amino acid sequence and biologi-
cal activity [12—131. These two peptides have a common 37
residues out of a total of 53. Human urogastrone will promote
early eyelid opening in mice and purified EGF can block
hydrogen chloride release from gastric mucosa.
Epidermal growth factor has been shown to stimulate DNA
synthesis and cell division in the nanograms per milliliter range
in numerous types of cultured cells, usually of epithelial or
endothelial origin [14—16]. Since EGF is easily extractable and
purified from mouse submaxillary glands [9] and is active in a
wide variety of cultured cell lines, it has become a valuable
reagent for cell culture and is a vital component of most
chemically defined media [17, 18]. A great deal of knowledge is
available concerning the mode of action of EGF in stimulating
cell proliferation. The probable mode of action of EGF, as well
as other growth factors, may involve endocytosis of the occu-
pied cell surface receptors and subsequent action within the cell
[19, 20]. There is also evidence that EGF becomes chemically
bound to its receptor [21, 22], and it has been shown recently
that antibodies to the purified receptor for EGF will mimic
some of the biological effects of the EGF [23]. The final
determination of its exact mode of action has yet to be
determined.
The most interesting aspect of EGF for this presentation is its
astoundingly wide variety of actions in vivo. As mentioned
above, EGF was originally isolated using the precocious eye
opening in newborn mice. In addition to this, studies in fetal
lambs have indicated that EGF stimulates epithelial growth in a
variety of sites, especially in upper and lower respiratory
airways [24]. Similar results have been reported in rabbits [25].
In adult mice, EGF has been found to stimulate DNA synthesis
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in the cecum, colon, and rectum as soon as 4 hr after injection
[26]. EGF also stimulates ornithine decarboxylase activity in
neonatal mouse stomach and duodenal tissue [27] and adult rat
liver DNA synthesis [281. This stimulation of epithelial cells in a
variety of sites raises the possibility that EUF may be a fetal
growth factor responsible for the proliferation of this cell type
during normal embryonic development.
Nerve growth factor. Extracts of mouse submaxillary gland
also contain another potent growth factor, nerve growth factor
(NGF). This polypeptide is isolated from the male mouse
submaxillary gland as a high molecular weight complex com-
monly termed 7S NGF [29, 301. As with the EGF described
previously, the 7S NGF is a complex composed of an arginine
esterase which converts a 22,000-dalton precursor polypeptide
to a 13,000-dalton NGF [31, 321 and afterwards serves as a
carrier molecule. The active low molecular weight segment of
NGF has been sequenced [33. 34]. The knowledge of the
sequence of NGF allows it to be placed in a subset of growth
factors termed the insulin-related growth factors due to its
similarity in sequence and structure to insulin [341. Other
members of this subset include the multiplication-stimulating
activity (MSA) [351 and the two insulin-like growth factors, I
and II, which have been sequenced recently [36]. These growth
factors have a similar biological property in that they all cause a
so-called pleotypic response in sensitive cells. This response is
usually defined as a general increase in cellular metabolism
involving DNA and protein synthesis and nutrient transport. A
pleotypic response need not, however, lead to eventual cell
proliferation. In fact. NGF is not directly mitogenic for its
target cells.
The biological activity of NGF differs considerably from that
found with EGF. These two growth factors represent the
opposite ends of the spectrum of activities generally ascribed to
growth factors, hyperplasia and hypertrophy. NGF is not
mitogenic for cultured nerve cells but acts as a survival agent.
In the embryo NGF acts to stimulate both sensory and sympa-
thetic nerve cells [39, 401. The NGF is mitogenic only during
early embryonic development, later only a hypertrophic re-
sponse is seen. In vitro, NGF is limited to a strictly survival
role: In its presence, cultures of NGF thrive: without it, they
quickly disintegrate and die [37—401. Similar effects may also
appear in in vivo experiments. For example, in the adult.
elimination of NOF by an autoimmune state or passive immuni-
zation leads to degeneration of both sensory and sympathetic
neurons [38. 411. Thus, as far as nerve cells are concerned.
NGF in adults is mainly a survival agent while in the embryo
NGF has a more active mitogcnic role.
Recently, another interesting possible role of NGF has been
found. it was originally observed that mice whose salivary
glands had been removed experienced delayed wound healing
[42]. This has been expanded by the finding that the topical
application of NGF to wounds on mice without salivary glands
lead to an acceleration of wound closure [431. This may partially
explain the presence and high levels of NGF in submaxillary
glands. This is an example of the same growth factor having a
role in both normal embryonic development and response to
injury.
Colony stimulating factor/macrophage growth factor. The
continual proliferation and maturation of bone marrow-derived
cells is one of the most important growth factor mediated
processes in mature animals. This continual production is
necessary to replace cells lost due to aging and involvement in
certain inflammatory reactions. An important subset of blood
cells we will deal with here are the granulocytes and macro-
phages. The production of these cells from the marrow is
controlled by a group of factors called colony stimulating factor
(CSF). The CSF activity is commonly assayed in vitro by
determining the number of granulocyte/macrophage colonies
formed in soft agar from a suspension of murine bone marrow
cells.
Colony stimulating activity has been collected from a variety
of sources. CSF has been found in submaxillary glands 1441 as
have the above-mentioned EGF and NGF. Another source is
human or mouse serum [45, 46]. The most common source is
media conditioned by growth of various types of cultured cells,
mainly the murine fibroblast L-cell line [47, 481. The CSF
purified from this source is a 60,000- to 70.000-dalton glycopro-
tein with an isoelectric point of 3.7 to 4.9. Reduction of the CSF
with 2-mercaptoethanol results in the formation of two subunits
of about 35,000 daltons which are devoid of biological activity.
A lower molecular weight factor, 23,000 daltons, with CSF
activity has also been reported from mouse lung fibroblasts
[49]. On gel filtration columns under nondenaturing conditions,
the CSF apparently aggregates into a large molecular weight
species of 190,000 daltons.
The purified CSF is active in vitro to promote colony
formation from murine marrow cells at a concentration of
approximately 3 ng/ml or 10_u M [47, 48]. The purified CSF has
been used to raise specific anti-CSF antibodies [48, 50]. These
antibodies have been used to show that the in vivo halflife of
injected CSF is about 1.5. The antibodies do not inhibit in vivo
granulopoesis but do show measurable effects in peritoneal
diffusion chambers [48, 51].
A structurally similar growth factor has been reported which
is capable of stimulating the proliferation of functionally mature
macrophages. This activity differs from the CSF in that the CSF
stimulates the maturation of granulocytes and macrophages
from common stem cells while the macrophage growth factor
(MGF) is a direct mitogen for mature macrophages. A MGF
from mouse lung fibroblast conditioned media has been purified
extensively [52, 53]. It is a 68,000-dalton glycoprotein with an
isoelectric point of 4.2. On polyacrylamide gel electrophoresis
under nondenaturing condition, multiple bands are seen at
progressively higher molecular weights possibly due to aggrega-
tion of the 68,000-dalton monomer,
The biological target cell of this MGF is the mature macro-
phage from the peritoneal exudate or a lung lavage. The dosage
for stimulating proliferation of these cells is about l0 M.
several orders of magnitude greater than that required for
colony formation by CSF. The strikingly similar chemical
properties of mouse L-cell CSF and MGF suggest that they may
represent the same or very similar molecules with different
effects depending on concentration [53]. The concentration of
MGF would be expected to he very high at sites of inflamma-
tory reactions leading to local expansion of the population of
functionally active macrophages. Outside the inflammatory
lesion, much lower levels would maintain the necessary level of
production of replacement cells.
T-cell growth factor. Another factor which can stimulate the
proliferation of a mature, functionally active population of cells
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is the recently recognized T-cell growth factor (TCGF) or in the
more current nomenclature, Interleukin-2 (IL-2). The IL-2 is
one of the soluble factors which can regulate the immune
response [54—561. IL-2 activity is found in a variety of condi-
tioned media produced by activated lymphocyte populations.
The activation can be produced by a variety of substances,
mitogens, alloantigens, or other foreign antigens [57—601. The
murine T-cell derived IL-2 is a protein of 30,000 daltons [601. It
is composed of two subunits with isoelectric points of 4.3 and
4.9. The rat and human IL-2 factors are of somewhat lower
molecular weights, between 20,000 and 12,000 [57—591. The
isoelectric points of the rat and human IL-2 activity is in the
acid range, 5.5 to 6.5.
The biological importance of the IL-2 or TCGF resides in its
ability to cause expansion of clones of activated T-cells [61—631.
The factor is essential for the continued culture of T-cell blasts
in culture with the maintenance of differentiated functions. The
IL-2 does not stimulate lymphocyte proliferation in the absence
of a previous antigenic or mitogenic signal. In this aspect, the
IL-2 is similar in action to the MGF as it only stimulates a
functionally mature cell population. Both these factors are
important in the regulation of the inflammatory response in fully
developed animals.
Injury repair
In addition to embryonic and developmental growth, a multi-
cellular organism is also constantly required to repair various
forms of damage to its integrity. This process involves both
wound repair such as closure of skin after punctures or cuts and
the regeneration of organ mass and function after damage
caused either by mechanical means or by chemicals. In this
section we will cover several examples of growth factors which
may be involved in each of these processes.
Platelet-derived growth factor. The in vitro culture of animal
cells requires the presence of some kind of serum for maximal
growth and survival. The various factors in serum responsible
for the growth-promoting activity have been a source of intense
investigation. The major growth-promoting activity in serum,
platelet-derived growth factor (PDGF) has been isolated and
characterized by several groups. The discovery of this factor
was based on the observation that cells would proliferate in
culture in media containing serum but not plasma. Subsequent-
ly, it was shown that PDGF was stored in the alpha granules of
blood platelets until released by the clotting process [64—671.
The PDGF has proven to be an essential component of the
media for cultured cells and, in addition, has provided valuable
information on the general mechanisms by which serum and
plasma components both contribute to the maintenance of cell
proliferation in culture.
The PDGF has been purified recently by several laboratories
[68—721. It is a basic polypeptide with an isoelectric point of 9.8
to 10.2 and about 13,000 daltons under reducing conditions.
Highly purified PDGF is active in stimulating cultured cells at
the 1 ng/ml level.
The in vitro activity of this factor has been a subject of
intense study. The PDGF supports the growth of a variety of
cell types, mainly of mesenchymal origin [641. This includes
fibroblasts mainly, but activity also includes glial cells [73] and,
most importantly, primate arterial smooth muscle cells [74].
Mechanistic studies [64, 75—78] have shown that the PDGF
controls some early point in the Go phase of the cell cycle and
that other factors, present in both serum and plasma, are also
necessary for cell growth.
The in vitro specificity of PDGF for mainly connective tissue
cells suggests the role that PDGF may play in vivo. The PDGF
may be involved in the repair of tissue following an injury, a
classic wound hormone. The packaging of the PDGF in the
granules of the platelet is also supportive of this suggestion as
the factor would only be released at the site of an injury where
clotting would occur. The released PDGF would then stimulate
only the cells immediately surrounding the injury. This is an
essential mechanism for a hormone which has as its target
connective tissue that is universally present throughout the
body, thus no organ-specific factor could exist as with the liver
or kidney. The stimulation of the vascular smooth muscle cells
has suggested that the PDGF may also be involved in athero-
sclerosis [79—80]. An injury to a vessel wall, as in experimental-
ly induced atherosclerosis, would trigger local clotting and
release of PDGF which could then stimulate the surrounding
vascular smooth muscle cells and begin the process of plaque
formation.
The general conclusions seem to be that the responsive cell
types in vitro and packaging of the PDGF within the platelet
makes this factor an ideal subject for the growth factor involved
in wound healing. This mechanism would obviously involve a
different delivery system than during embryonic growth as only
the cells in a limited area need respond.
Fibroblast growth factor. A protein similar to PDGF has been
isolated and characterized from bovine brain and pituitary. This
factor, fibroblast growth factor (FGF), is also a basic polypep-
tide with an isoelectric point of 9.6 and a molecular weight of
13,000 daltons [81, 82]. Chemically, this factor is strikingly
similar to PDGF, but its biological activity clearly distinguishes
the two. The FGF is a potent mitogen in vitro mesoderm-
derived cells, especially vascular and corneal endothelial cells
at the same level of purified PDGF, that is, 1 ng/ml or M
[83, 84]. Vascular endothelial cells grown in the presence of
FGF form a tightly packed cell layer which is morphologically
similar to that observed in vitro [85, 86]. The brain FGF has also
been shown to be an angiogenic factor in vivo [87]. This may be
related to its potent stimulation of the vascular endothelial cells
mentioned above. It is interesting to speculate that the PDGF
and FGF with their complementary activities for vascular
tissues would work in concert to generate new vessels during
wound repair. Purified FGF has been reported to stimulate the
growth of bastemal cells of frogs [83, 88]. This has led to the
suggestion that FGF, or a similar factor, may be involved in the
initial stages of repair and regrowth of amputation injuries in
lower vertebrates. This would certainly qualify it as a candidate
for a wound hormone.
Kidney and liver growth factors. There is another instance
where growth factor activity has been implicated in wound
repair. This is the case of the regrowth of the function of certain
organs after injury. This is commonly called compensatory
growth and encompasses both the restoration of the original
level of function and eventually the original size. There are two
organs that we will discuss which are capable of compensatory
growth, the kidney and the liver. The kidney is capable of
returning to a significant portion of its original output following
injury (either due to disease or experimentally by removal of
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one of the pair) by both hypertrophy and hyperplasia [89].
Considerable evidence has accumulated to implicate humoral
factors, renotropins, in this repair process. This has been done
in several ways, either by injecting serum from uninephrecto-
mized animals into test animals [90, 91] or in experiments with
parabiotic pairs [92]. Biochemical evidence suggests that the
renotropic factor may be a heat stable polypeptide of less than
25,000 daltons which is organ specific [93]. Renotropic factors
have also been reported in urine [94. 951.
There is evidence that the regeneration of damaged liver
tissue may also be under the control of hurnoral growth factors.
A protein factor of 30,000 to 50,000 daltons has been identified
in both the serum from partially hepatectomized rats and in the
extracts of the regenerating liver [96—98]. This factor was found
to be specific for liver in vivo with no activity on the kidney or
spleen. A similar factor has been identified in the serum of rats
with liver damage induced chemically by thioacetamide [99].
This factor was active in vivo upon injection into either rats or
mice. These factors may be similar or identical to factors acting
in normal developmental growth or even in neoplastic condi-
tions as it has been shown recently that hepatic stimulatory
factors are present in extracts of both weariling or regenerating
adult liver [100] and Ehrlich ascites carcinoma fluid [101].
Neoplastic growth
The third biological situation in which growth factors play an
important role is in the rapid cellular proliferation associated
with the various neoplasms. Whether this abnormally high
growth role is due to increased sensitivity to normal levels of
growth factors or to increased production of new factors is
under intense investigation.
TransJrming growth factors. One of the most interesting
aspects of growth factor research recently has been the discov-
ery of a class of factors produced by tumor cells which have the
ability, in vitro, to cause normal cells to morphologically
resemble tumor cells. This discovery arose from the long
observed phenomenon that tumor cells in culture required less
serum to grow and survive than the corresponding normal cells.
Todaro and Delarco [102] first described that certain sarcoma
virus transformed cells bound far less labeled EGF than their
normal counterparts or cells transformed by other means.
These studies were expanded subsequently by the finding that
the sarcoma virus-transformed cells produced a factor which
bound to the EGF receptors on the cell surface [103. 104].
These sarcoma growth factors (SGF) were produced in such
quantity that the available surface receptors were always occu-
pied and thus the cells apparently possessed fewer receptors for
labeled EGF.
The biological activity of the SGF is quite amazing when they
are tested with cultures of normal cells. The SGF can induce in
these normal cells all the biological manifestations of trans-
formed cells normally seen in culture [103. 105]. This includes
the stimulation of growth-arrested normal cells to continue
division above a saturation level normally inhibitory to further
growth and the ability of normal cells to form colonies in soft
agar suspension culture. This property was formerly considered
a prime difference between normal and transformed cells in
culture. The morphology of the normal cells also changes to one
resembling the transformed cells. The most interesting aspect of
the biological effects of the SGF is that they are totally
dependent on the continued presence of the SGF in the growth
medium, and the normal phenotype is returned if the SGF-
containing media is replaced with normal culture media. The
EGF produces none of the effects previously mentioned.
The SGF from the culture media of murine sarcoma virus
transformed fibroblasts while binding to the EGF receptors is
distinct from the EGF biochemically and biologically. The SGF
is a heat-stable, trypsin and thiol reagent sensitive polypeptide
which does not cross-react with anti-EGF antibodies [103].
There are three active molecular weight species detectable by
gel filtration: 25,000, 12,000, and 7,000. Polypeptides with the
same biological properties have been extracted from the sarco-
ma virus-transformed cells grown in culture and from chemical-
ly induced tumors in mice [1061 by an acid/ethanol extraction
procedure. In this case the major biological activity was in the
7000-dalton species.
The discovery of the SGF and other transforming growth
factors (TGF's) from animal and human tumors and tumor cell
lines [104, 107] has resulted in the theory that tumor cells can
maintain their rapid growth and anchorage independence in part
by the autocrine production of their own growth factors [108.
1091. In many of their functions, the lGF's may resemble
factors which are required during normal embryonic develop-
ment. Recently. polypeptides which are indistinguishible both
biochemically and in their biological activity have been isolated
from mouse embryos [110] and from many non-neoplastic
sources such as submaxillary gland, kidney, liver, heart and
brain [Ill]. It has also been shown that during embryonic
development, at certain stages there is more EGF-receptor
binding activity than can be accounted for by imniunoreactive
EGF, also suggesting factors which bind EGF receptors but
which chemically are different from EGF [112]. These findings
suggested that the differences between neoplastic and non-
neoplastic cells may be more quantitative rather than qualita-
tive. The ongoing study of the TGF's will certainly lead to a
better understanding of both the normal and abnormal growth
control mechanisms.
Tumor angiogenic factors. Another growth factor found
associated with neoplastic cells is the angiogenic stimulating
activity. Angiogenesis. the formation of new blood vessels, is
critical to the survival of solid tumors, and it is a long recog-
nized phenomenon that tumor cells secrete angiogenesis fac-
tors, TAF's [113]. This has been observed by assaying both
growing tumor fragments and various extracts in viva using
mainly in the chick chorioallantoic membrane or rabbit corneal
micropocket assays. Recently, an in vitro assay using fetal
bovine aortic endothelial cell cultures has been developed [114].
The angiogenic factor(s) must possess several biological activi-
ties, that is. it must be both chemotactic and mitogenic for
vascular endothelial cells. The use of the in vitro mitogenic
assay with endothelial cell cultures followed by the in vivo
assays mentioned above has allowed the purification to a great
degree of tumor angiogenic factor. The TAF was isolated
originally as a large molecular weight complex containing RNA,
protein, and carbohydrate 115] but subsequent investigations
show that the biological activity resides in a very low molecular
weight factor (less than 1000 daltons) whose structure still
remains to be elucidated 1114, 116. 117]. As with the transform-
ing growth factors, similar angiogenic factors have also been
identified from normal tissue sources [113. 118]. Two higher
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molecular weight angiogenic factors, 50,000 and 70,000 daltons,
have been isolated recently from bovine retina [1191. It did not
appear that these high molecular weight factors were carriers
for the low molecular weight factor similar to TAF as the
activity was stable after acid treatment and denaturing reagents.
The purification and final characterization of the TAF as well as
those from normal tissues will be of great importance in the
study of how tumors interact with the host animal. The survival
importance of neovascularization to tumor growth is shown by
the inhibition of tumor growth in vivo by infusion of a partially
purified angiogenesis inhibitor [120]. This angiogenesis inhibitor
was not directly inhibitory to the tumor cells in culture even at
high concentrations.
Angiogenic factors present in nontumor tissue samples or
serum are obviously involved in processes not involved with
tumor growth. Angiogenesis is of importance in several other
situations such as wound repair and in normal growth. As
mentioned previously, FGF has been noted to possess angio-
genic activity [871 possibly important for its potential role in
wound healing and regeneration. It has also been noted that
certain aspects of an inflammatory response also are capable of
eliciting endothelial cell proliferation in vivo and neovasculari-
zation in vivo. For example, mitogen-activated spleen cells and
the conditioned media from these cells is capable of inducing
new vesicle in the chorioallantoic membrane assay of chicken
eggs [121]. A macrophage-derived factor has been identified
which can stimulate the proliferation of fibroblasts, vascular
smooth muscle cells and vascular endothelium [122]. This
factor was characterized as a nondialyzable, heat-labile, disul-
fide-containing protein. The migration of this factor through
ion-exchange columns indicated that it was not PDGF or FGF.
The results linking inflammatory cells and vascularization are
supported by observations resulting from thermal injury to rat
skin [123]. In these studies, acute inflammation was initiated by
a thermal injury of 60°C for 20 sec, which was followed by
endothelial cell proliferation within 1 to 3 days and new
vascularization at 5 to 7 days. Such effects could have been
mediated by angiogenic factors released from cells participating
in the inflammatory response.
Summary
In the preceding sections we have shown evidence that
growth-promoting factors are involved in three basic situations.
In normal embryonic development and function of mature
organisms, growth factors such as NGF and EGF are of prime
importance in supporting the necessary embryonic cell prolif-
eration and the development of specific cell types. Other factors
operate on subsets of mature cells during specialized functions
such as inflammation. Included in this set would be factors such
as CSF/MGF and Interleukin-2.
Another basic function of growth factors has been shown to
be wound repair and organ regeneration. This includes the well
characterized PDGF and FGF as well as the various renotropic
factors and liver growth factors. As these factors must operate
in mature organisms with many different cell types and similar
cell types in many locations, more specificity is needed than in
embryonic growth. This has resulted in the organ specific
factors such as the renotropins and in the unique delivery
system of the PDGF.
The recent discovery and characterization of the transform-
ing growth factors has provided a possible connection between
embryonic and normal developmental growth and the rapid
cellular proliferation characteristic of tumor cells. The TGF not
only interacts with receptors for normal growth factors such as
EGF but are also detectable in low levels in normal tissue and
embryos. The exact relationships between these various factors
will have to await the determinations of more amino acid
sequences for comparisons. The other tumor-related product,
tumor angiogenesis factor, is also found in normal tissue and
inflammatory reaction sites.
Any presentation of the biological function of the various
growth factors must include their role in the growth control
process. Obviously, growth factors are involved in the initiation
at some point of division in sensitive cells. As shown here, this
process can be regulated by limiting the cell types sensitive for
certain factors or by limiting the distribution of the factor as
with the PDGF. There is also evidence for the presence of
inhibitors of cell growth with, in many instances, specificities
analogous to the growth factors presented here. We will not
present a detailed discussion of the various growth inhibitors
and their possible interactions with growth stimulators. A major
obstacle to the assignment of roles to growth inhibitors has been
a lack of well defined inhibitors with which to study their
biological interactions. To date, no inhibitor has been charac-
terized to the extent that EGF or NGF has been. This,
combined with the inherent difficulties in studying growth
inhibition free of nonspecific toxic effects greatly hindered the
development of theories concerning interactions of growth
factors and inhibitors.
Generally, there are reports of growth inhibitors for most of
the stimulators mentioned here. For example, there is consider-
able evidence for epidermal cell inhibitors [124, 125], as well as
smooth muscle [126], liver [127—129], granulocyte [130, 131],
lymphocyte inhibitors [1321, and many others [61. It has been
proposed that cell growth is controlled by cell-specific, endoge-
nous reversible inhibitors of cell division usually termed cha-
lones [6, 7]. These chalones function normally to restrain cells
from proliferation, possibly by preventing the actions of growth
factors. There is some experimental evidence to suggest that
the action of inhibitors may be counteracted by specific growth
factors [133, 134].
The general function of growth factors and growth inhibitors
(chalones) is to keep the cell number in balance such as to
maintain tissue homeostasis. The final determination of the
relative role each plays in this process is yet to be resolved.
There are many functions of a mature organism which require
rapid local proliferation of a small population of cells or the
continued proliferation of one specific cell type. Both growth
stimulators and inhibitors are involved in the initiation, mainte-
nance, and final cessation of cellular proliferation.
Reprint requests to Dr. L. M. Patt, Virginia Mason Research Center,
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